Kidney Transplant Infection Clinical Trial
Official title:
Prevalence of BK Viremia in Simultaneous Liver-Kidney Transplant Recipients: A Retrospective Single-Center Review
The human BK polyomavirus is a significant risk factor for renal transplant dysfunction and allograft loss. The prevalence of BK viremia (BKV) following kidney transplantation is estimated to be 10-20%.
The human BK polyomavirus is a significant risk factor for renal transplant dysfunction and allograft loss. The prevalence of BK viremia (BKV) following kidney transplantation is estimated to be 10-20%. Immunosuppression reduction is the management cornerstone for BKV and has been shown to be effective at clearing the virus while maintaining graft function in both kidney alone and simultaneous kidney-pancreas transplant recipients. However, there is a lack of published data on the prevalence and outcomes in simultaneous liver-kidney (SLK) transplant recipients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02439957 -
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus
|
Phase 3 | |
| Not yet recruiting |
NCT06364618 -
Use of Wearables to Detect Infections in Kidney Transplant Recipients
|
||
| Completed |
NCT05142748 -
Study of Pulmonary Infections (Pneumonia) in Kidney Transplant Recipients Admitted to Hospital
|
||
| Terminated |
NCT05747053 -
Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
|
||
| Completed |
NCT03339661 -
Secondary Prophylaxis After CMV Disease in Kidney Transplant Patients Targeted by γδ T Cells Immunomonitoring.
|
Phase 2 | |
| Recruiting |
NCT04701528 -
Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients
|
Phase 2 | |
| Recruiting |
NCT04494776 -
SARS-COV-2 Infection in Kidney Transplant Recipients: a Brazilian Multicenter Study
|
||
| Completed |
NCT02263703 -
Immunogenicity of HPV Vaccine in Immunosuppressed Children
|
Phase 3 | |
| Recruiting |
NCT06219616 -
Prediction of BK Virus Reactivation in Kidney Transplant Recipient
|
N/A | |
| Not yet recruiting |
NCT05708534 -
Evolution of CMV Antiviral T-cell Immunity Over the Next Six Months Initiation of Treatment With Belatacept.
|
||
| Recruiting |
NCT03488771 -
Evaluation of Cell-mediated Immune Response by QuantiFERON Monitor® Assay in Kidney Transplant Recipients
|
||
| Recruiting |
NCT04815954 -
Early vs Late Urinary Catheter Removal After Renal Transplantation
|
N/A | |
| Recruiting |
NCT05727709 -
Dynamic Changes of Torquetenovirus (TTV) Load in Chinese Renal Transplant Recipients
|
||
| Completed |
NCT04542954 -
Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience From the Middle East
|
||
| Active, not recruiting |
NCT03924219 -
CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients
|
||
| Recruiting |
NCT05836636 -
Immune Monitoring of Prevalent Kidney Transplant Recipients Using Torque Teno Virus: A Single-Center, Prospective Cohort Study
|
||
| Not yet recruiting |
NCT06407232 -
Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
|
Phase 3 | |
| Completed |
NCT03468478 -
Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation
|
Phase 4 | |
| Recruiting |
NCT05397821 -
Pediatric Kidney Transplantation, Ureteroneocystostomy Techniques
|
||
| Not yet recruiting |
NCT05316038 -
Metabolic and Infectious Complications Post Belatacept Conversion
|